Altimmune Inc (ALT) - Total Assets
Based on the latest financial reports, Altimmune Inc (ALT) holds total assets worth $279.93 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Altimmune Inc to assess how comfortably operating cash covers total debt obligations.
Altimmune Inc - Total Assets Trend (2005–2025)
This chart illustrates how Altimmune Inc's total assets have evolved over time, based on quarterly financial data. See ALT net asset value for net asset value and shareholders' equity analysis.
Altimmune Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Altimmune Inc's total assets of $279.93 Million consist of 99.4% current assets and 0.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.6% |
| Accounts Receivable | $1.74 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Altimmune Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ALT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Altimmune Inc's current assets represent 99.4% of total assets in 2025, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2025, up from 2.0% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Altimmune Inc Competitors by Total Assets
Key competitors of Altimmune Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Altimmune Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.55 | 13.11 | 24.96 |
| Quick Ratio | 18.55 | 13.11 | 24.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $263.19 Million | $126.79 Million | $235.37 Million |
Altimmune Inc - Advanced Valuation Insights
This section examines the relationship between Altimmune Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.12 |
| Latest Market Cap to Assets Ratio | 1.27 |
| Asset Growth Rate (YoY) | 100.9% |
| Total Assets | $279.93 Million |
| Market Capitalization | $355.66 Million USD |
Valuation Analysis
Above Book Valuation: The market values Altimmune Inc's assets above their book value (1.27x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Altimmune Inc's assets grew by 100.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Altimmune Inc (2005–2025)
The table below shows the annual total assets of Altimmune Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $279.93 Million | +100.95% |
| 2024-12-31 | $139.31 Million | -33.87% |
| 2023-12-31 | $210.64 Million | +1.79% |
| 2022-12-31 | $206.93 Million | -5.45% |
| 2021-12-31 | $218.86 Million | -10.71% |
| 2020-12-31 | $245.12 Million | +353.43% |
| 2019-12-31 | $54.06 Million | -1.26% |
| 2018-12-31 | $54.75 Million | -13.14% |
| 2017-12-31 | $63.03 Million | -71.95% |
| 2016-12-31 | $224.74 Million | +1031.48% |
| 2015-12-31 | $19.86 Million | -9.63% |
| 2014-12-31 | $21.98 Million | +28.23% |
| 2013-12-31 | $17.14 Million | -24.63% |
| 2012-12-31 | $22.74 Million | -0.27% |
| 2011-12-31 | $22.80 Million | -16.16% |
| 2010-12-31 | $27.20 Million | -20.16% |
| 2009-12-31 | $34.07 Million | -39.59% |
| 2008-12-31 | $56.39 Million | -15.34% |
| 2007-12-31 | $66.61 Million | -7.15% |
| 2006-12-31 | $71.74 Million | +2.36% |
| 2005-12-31 | $70.09 Million | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.